Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lantern Pharma Inc. before investing.

In this article, we go over a few key elements for understanding Lantern Pharma Inc.’s stock price such as:

• Lantern Pharma Inc.’s current stock price and volume
• Why Lantern Pharma Inc.’s stock price changed recently
• Upgrades and downgrades for LTRN from analysts
• LTRN’s stock price momentum as measured by its relative strength

About Lantern Pharma Inc. (LTRN)

Before we jump into Lantern Pharma Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Want to learn more about Lantern Pharma Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lantern Pharma Inc..

Lantern Pharma Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Lantern Pharma Inc.’s stock price was $2.630.

Lantern Pharma Inc. is down 0.75% from its previous closing price of $2.650.

During the last market session, Lantern Pharma Inc.’s stock traded between $2.570 and $2.870. Currently, there are approximately 11.25 million shares outstanding for Lantern Pharma Inc..

Lantern Pharma Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lantern Pharma Inc. Stock Price History

Lantern Pharma Inc.’s (LTRN) price is currently down 36.93% so far this month.

During the month of July, Lantern Pharma Inc.’s stock price has reached a high of $4.340 and a low of $2.510.

Over the last year, Lantern Pharma Inc. has hit prices as high as $5.744 and as low as $1.110. Year to date, Lantern Pharma Inc.’s stock is down 13.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lantern Pharma Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Lantern Pharma Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Lantern Pharma Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lantern Pharma Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lantern Pharma Inc. (LTRN) by visiting AAII Stock Evaluator.

Relative Price Strength of Lantern Pharma Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Lantern Pharma Inc. has a weighted four-quarter relative price strength of -6.99%, which translates to a Momentum Score of 31 and is considered to be Weak.

Want to learn more about how Lantern Pharma Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lantern Pharma Inc. Stock Price: Bottom Line

As of July 31, 2026, Lantern Pharma Inc.’s stock price is $2.630, which is down 0.75% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lantern Pharma Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.